ERBB2 and breast carcinoma: Besides being a poor prognosis marker (Dowsett et al, 2003), ERBB2 amplification is a predictive marker for targeted therapy with the monoclonal antibody trastuzumab in breast cancer patients with metastatic disease (Slamon et al, 2001).